| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Capturing the true burden of Shigella and ETEC: The way forward
|
Khalil, Ibrahim
|
|
2019
|
37 |
34 |
p. 4784-4786
|
article
|
| 2 |
Clinical endpoints for efficacy studies
|
Porter, Chad K.
|
|
2019
|
37 |
34 |
p. 4814-4822
|
article
|
| 3 |
Editorial Board/Aims and Scope
|
|
|
2019
|
37 |
34 |
p. IFC
|
article
|
| 4 |
How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?
|
Giersing, Birgitte K.
|
|
2019
|
37 |
34 |
p. 4778-4783
|
article
|
| 5 |
How genomics can be used to understand host susceptibility to enteric infection, aiding in the development of vaccines and immunotherapeutic interventions
|
Mottram, Lynda
|
|
2019
|
37 |
34 |
p. 4805-4810
|
article
|
| 6 |
Implications and measurement of herd protection (indirect effects) for enteric vaccine development
|
Wierzba, Thomas F.
|
|
2019
|
37 |
34 |
p. 4775-4777
|
article
|
| 7 |
Preface
|
Walker, Richard I.
|
|
2019
|
37 |
34 |
p. 4767
|
article
|
| 8 |
Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development
|
Mani, Sachin
|
|
2019
|
37 |
34 |
p. 4787-4793
|
article
|
| 9 |
Technical product attributes in development of an oral enteric vaccine for infants
|
White, Jessica A.
|
|
2019
|
37 |
34 |
p. 4800-4804
|
article
|
| 10 |
The way forward for ETEC controlled human infection models (CHIMs)
|
Hanevik, Kurt
|
|
2019
|
37 |
34 |
p. 4794-4799
|
article
|
| 11 |
Using advocacy to increase investment in enteric vaccine development
|
Randall, Hope
|
|
2019
|
37 |
34 |
p. 4811-4813
|
article
|
| 12 |
Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference
|
Barry, Eileen
|
|
2019
|
37 |
34 |
p. 4768-4774
|
article
|
Journal description